Source - SMW
Vectura Group confirms the announcement by alliance partner Novartis that new analyses from the head-to-head FLAME study confirmed Ultibro Breezhaler is a more effective option for patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups (exacerbations) than Seretide.

This confirmation applied to different patient sub-groups.

In the new analyses, once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of all exacerbations (mild, moderate and severe), regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels (a type of white blood cells) and previous inhaled corticosteroid (ICS) use, versus twice-daily Seretide 50/500 mcg.

Specifically, among patients with the severest forms of COPD, Ultibro Breezhaler significantly reduced the rate of exacerbations and improved their health status versus the commonly used ICS/LABA combination. In addition, patients using Ultibro Breezhaler needed less rescue medication during the day.

Related Charts

Vectura Group (VEC)

-3.45p (-2.48%)
delayed 16:40PM